Edition:
United States

Hua Han Health Industry Holdings Ltd (0587.HK)

0587.HK on Hong Kong Stock

0.53HKD
--
Change (% chg)

-- (--)
Prev Close
HK$0.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
HK$0.87
52-wk Low
HK$0.41

Latest Key Developments (Source: Significant Developments)

Hua Han Health Industry clarifies on second allegation report from Emerson Analytics Co.<0587.HK>
Tuesday, 6 Sep 2016 09:44am EDT 

Hua Han Health Industry Holdings Ltd <0587.HK>: Further clarification announcement in relation to the second allegation report . Board confirmed not been contacted or interviewed by Emerson before issuance of second allegation report to verify data . Refers to announcement of co dated 29 August in relation to clarification of allegations contained in the negative report . Holding of 80% interest in Changdu Kangyuan enabled group to legally enjoy economic benefits of Changdu Kangyuan . Advised by its PRC legal advisers that such nominee arrangement did not violate PRC laws, would be legal and valid . Reserves the right to take legal action against Emerson and those who are responsible for the Emerson reports .Says the board vigorously denies the allegations against the group in the second allegation report.  Full Article

Emerson analytics responds to Hua Han Health's clarification on its manufacturing units<0587.HK>
Sunday, 28 Aug 2016 09:44pm EDT 

Emerson analytics: Refers to Hua Han health's clarification dated August 18 . Investigations show that of all Hua Han units, only Tibet Changdu Kangyuan Pharma is qualified as distributor of pharma products . Says "revenue contribution from Changdu Kangyuan is pure fiction", "also doubtful if Changdu Kangyuan really had any business" .  Full Article

Hua Han Health Industry Holdings announces share repurchase<0587.HK>
Thursday, 18 Aug 2016 08:32am EDT 

Hua Han Health Industry Holdings Ltd <0587.HK>: Health-voluntary announcement share repurchase <0587.HK> . Repurchased on market a total of 137,000,000 shares, representing approximately 1.85% of the issued share capital of the company . Says the aggregate consideration for the repurchase of shares is approximately hk$78.4 million . It has exercised its power under the general mandate to repurchase shares of the company granted by the shareholders . Highest purchase price per share was hk$0.62, the lowest purchase price per share was hk$0.53 and the average purchase price was approximately hk$0.5719 . Believes that the shares have been trading at a level which undervalues the company's performance and underlying value" . Believes it will be able to maintain strong financial position while continuing to grow its operations . Says pursuant to the repurchase mandate, the company is allowed to repurchase up to 739.3 million shares .  Full Article

Hua Han Health Industry reponds to Emerson allegations; applies for trading resumption<0587.HK>
Wednesday, 17 Aug 2016 08:17pm EDT 

Hua Han Health Industry Holdings Ltd <0587.HK>: Health-clarification announcement and resumption of trading <0587.HK> . Announcement is made to refute the allegations concerning the group in the allegation report . Application made for resumption of trading in shares and debt securities with effect from 9:00 a.m. on 18 August 2016 . Says allegations in the allegation report are malicious, untrue and groundless . Refers to announcement of co dated 11 August in relation to suspension of trading in the company's shares . Confirmed not been contacted or interviewed by Emerson before issuance of allegation report . Allegation report was published merely out of emerson's possible gains as a short seller of securities . Disagrees with revenue from sales by group as claimed in emerson report" . Vigorously denies allegations against group in allegation report; considers information contained in allegation report to be incomplete . Allegations from Emerson resulted in "significant" losses of group's human resources, financial resources . Reserves right to take legal action against Emerson for allegation report"; to hold it responsible for all losses caused to group .  Full Article

Hua Han Health Industry announces issue of senior notes due 2019<0587.HK>
Friday, 10 Jun 2016 10:49am EDT 

Hua Han Health Industry Holdings Ltd <0587.HK>: Health-issue of US$150,000,000 7 per cent. senior notes due 2019 and disclosure pursuant to rule 13.18 of the listing rules <0587.HK> . Net proceeds from the senior notes issue are estimated to amount to approximately US$147.1 million . The company and the subsidiary guarantors entered into the purchase agreement with Haitong International .  Full Article

Hua Han Health Industry updates on acquisition of shares by a substantial shareholder<0587.HK>
Thursday, 26 May 2016 08:00am EDT 

Hua Han Health Industry Holdings Ltd <0587.HK>: Health-voluntary announcement acquisition of shares by a substantial shareholder <0587.HK> . Co was informed that Bull's- Eye ltd acquired 7.4 million shares of the company on 26 May 2016 from open market purchase .  Full Article

Hua Han Health Industry says Bull'S-Eye acquired 9.6 mln shares of company<0587.HK>
Wednesday, 25 May 2016 08:16am EDT 

Hua Han Health Industry Holdings Ltd <0587.HK>: Health-voluntary announcement acquisition of shares by a substantial shareholder <0587.HK> . Informed by Bull'S-Eye that Bull'S- Eye Limited acquired 9.6 million shares .  Full Article

Hua Han Bio-Pharmaceutical Holdings says enters into strategic cooperation agreement
Monday, 24 Aug 2015 07:06am EDT 

Hua Han Bio-Pharmaceutical Holdings Ltd:Says unit entered into a strategic cooperation agreement with the Shanghai Jiao Tong University School of Medicine.Strategic Cooperation Agreement will facilitate the rapid development of the medical service business of the Group, which will be beneficial to the Group and the shareholders of the Company as a whole.  Full Article

More From Around the Web

BRIEF-Hua Han Health Industry updates on purchase of senior notes

* US$150 mln 7% senior notes due 2019 offer to purchase for cash any and all outstanding 7.00% senior notes due 2019